Williams and his team suggested that the BCR-ABL fusion gene and CDKN2 deletion interferes with the tumor suppressor network of Rb and p53, thereby accelerating the self-renewal of leukemia initial cells and enhancing its resistance to the drug [37]. The gene discussed is ABL1; the disease is neoplasm.